Advanced search

Irbesartan is projected to be cost and life saving in the French setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria

(2003) VALUE IN HEALTH. 6(6). p.615-616
Author
Organization

Citation

Please use this url to cite or link to this publication:

Chicago
Palmer, AJ, Lieven Annemans, S Roze, M Lamotte, P Lapuerta, S Gabriel, R Chen, et al. 2003. “Irbesartan Is Projected to Be Cost and Life Saving in the French Setting for Treatment of Patients with Type 2 Diabetes, Hypertension, and Microalbuminuria.” In Value in Health, 6:615–616.
APA
Palmer, AJ, Annemans, L., Roze, S., Lamotte, M., Lapuerta, P., Gabriel, S., Chen, R., et al. (2003). Irbesartan is projected to be cost and life saving in the French setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. VALUE IN HEALTH (Vol. 6, pp. 615–616).
Vancouver
1.
Palmer A, Annemans L, Roze S, Lamotte M, Lapuerta P, Gabriel S, et al. Irbesartan is projected to be cost and life saving in the French setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. VALUE IN HEALTH. 2003. p. 615–6.
MLA
Palmer, AJ, Lieven Annemans, S Roze, et al. “Irbesartan Is Projected to Be Cost and Life Saving in the French Setting for Treatment of Patients with Type 2 Diabetes, Hypertension, and Microalbuminuria.” Value in Health. Vol. 6. 2003. 615–616. Print.
@inproceedings{306078,
  author       = {Palmer, AJ and Annemans, Lieven and Roze, S and Lamotte, M and Lapuerta, P and Gabriel, S and Chen, R and Carita, P and Vialladary, I and Rodby, R and De Zeeuw, D and Parving, HH},
  booktitle    = {VALUE IN HEALTH},
  issn         = {1098-3015},
  language     = {eng},
  number       = {6},
  pages        = {615--616},
  title        = {Irbesartan is projected to be cost and life saving in the French setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria},
  volume       = {6},
  year         = {2003},
}

Web of Science
Times cited: